RECENT FUNDING
  1. Recent Funding
  2. Companies
  3. Azafaros

Azafaros

Azafaros develops therapeutic agents for rare metabolic disorders, specifically lysosomal storage disorders.

Latest funding

$150M Series B+ ·

Led by Forbion Capital Partners · Source: startupintros.com

Total raised: $177M across 2 sourced rounds

All 2 rounds ↓
Website: azafaros.com.
LinkedIn: linkedin.com.
Sectors: Biotechnology, Health Care, Pharmaceutical, Therapeutics.
Stage: Series B+.
Based in: Leiden, The Netherlands.
Total raised: $177M in 2 sourced rounds.
Last round: May 13, 2025 · 552 days ago.
Headcount: 11–50 employees.
On Recent Funding since: Oct 1, 2026.

Signals

Website registeredApr 17, 2018 (8 years old)
About Azafaros

It focuses on an orally available azasugar, nizubaglustat, designed to treat the central nervous system and interfere with glycosphingolipid metabolism. Azafaros licenses these agents.

TIMELINE · MONEY RAISED

Azafaros | 655 days from website to first raise on record

Raised $177M in 2 sourced rounds·1 signal before the first raise
$44M$89M$133M$177MMAYJULSEPNOVJAN 2023MARMAYJUL$177M||WEBSITE CREATED · APR 17, 2018$27M Series A · Feb 1, 2020$27M A · FEB '20$150M Series B+ · May 13, 2025$150M B+ · MAY '25

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

DateRoundAmountLeadSource
Series B+$150MFForbion Capital Partnersstartupintros.com
Series A$27MFForbion Capital Partnersstartupintros.com

Timeline

  1. Website created

Founders and team

Investors

Companies like Azafaros

Other companies backed by Forbion Capital Partners

Forbion Capital Partners portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/azafaros (get a free API key).

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy